Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Analysts rate Fulcrum a "Moderate Buy": ten analysts cover the stock (7 buys, 2 sells, 1 hold) with an average 12‑month price target of $19.00.
• Positive clinical momentum: PIONEER trial data for pociredir/FTX‑6058 showed robust fetal‑hemoglobin induction and improved hemolysis/anemia markers, and the appointment of Dr. Josh Lehrer strengthens the board's sickle‑cell development expertise.
• Mixed financial/signaling backdrop: Q1 EPS beat modestly (‑$0.25 vs. ‑$0.31 expected) but the company remains loss‑making (analysts expect negative EPS for the year) while recent insider and institutional selling may pressure the stock, which is trading around $7.44.

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) have earned an average recommendation of "Moderate Buy" from the ten analysts that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $19.00.

Several analysts have recently weighed in on FULC shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Fulcrum Therapeutics in a report on Tuesday, April 21st. Truist Financial set a $17.00 target price on Fulcrum Therapeutics in a research report on Tuesday, February 24th. Leerink Partners restated an "outperform" rating on shares of Fulcrum Therapeutics in a research report on Tuesday, February 24th. JPMorgan Chase & Co. began coverage on Fulcrum Therapeutics in a research report on Monday, January 12th. They set an "overweight" rating and a $20.00 target price for the company. Finally, Wall Street Zen downgraded Fulcrum Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Sunday, April 12th.

Key Stories Impacting Fulcrum Therapeutics

Here are the key news stories impacting Fulcrum Therapeutics this week:

• Positive Sentiment: Q1 earnings beat consensus: Fulcrum reported EPS of -$0.25 vs. -$0.31 expected, a modest upside that investors view as a near‑term financial positive. Fulcrum Shares Climb After Q1 Earnings Outperform Expectations
• Positive Sentiment: Strong clinical readouts for pociredir: Company presented PIONEER trial data showing robust, rapid fetal hemoglobin (HbF) induction, improved hemolysis/anemia markers and encouraging trends on VOC reduction — results that materially de‑risk the lead program and support long‑term value creation if confirmed. Fulcrum Announces Business Highlights and Q1 Results
• Positive Sentiment: Board strengthening: Appointment of Dr. Josh Lehrer (experienced in sickle‑cell drug development, including Oxbryta) adds relevant development and commercial expertise ahead of pociredir’s next milestones. Fulcrum Appoints Josh Lehrer to Board
• Neutral Sentiment: Management commentary/transcripts available: Quarterly call and transcripts reiterated clinical progress and next operational priorities but offered no major new guidance or near‑term commercialization timetable, leaving catalysts spread over future data/regulatory events. Q1 2026 Earnings Call Highlights
• Negative Sentiment: Insider and institutional selling: Recent disclosures show material sales by major holders (RA Capital and other insiders/institutions), which may pressure the stock via supply overhang or investor concern about near‑term returns. QuiverQuant Coverage (insider & institutional activity)
• Negative Sentiment: Company remains loss‑making and analysts expect continued negative EPS for the year, which can limit upside until later‑stage clinical/regulatory de‑risking or clearer commercial outlook. MarketBeat Q1 Earnings Summary & Analyst Forecasts

Hedge Funds Weigh In On Fulcrum Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Aberdeen Group plc lifted its position in shares of Fulcrum Therapeutics by 135.0% during the 3rd quarter. Aberdeen Group plc now owns 137,961 shares of the company's stock worth $1,269,000 after buying an additional 79,265 shares during the period. Braidwell LP bought a new position in shares of Fulcrum Therapeutics during the 3rd quarter worth approximately $2,019,000. Boothbay Fund Management LLC lifted its position in shares of Fulcrum Therapeutics by 104.2% during the 3rd quarter. Boothbay Fund Management LLC now owns 678,414 shares of the company's stock worth $6,241,000 after buying an additional 346,136 shares during the period. Campbell & CO Investment Adviser LLC bought a new position in shares of Fulcrum Therapeutics during the 3rd quarter worth approximately $943,000. Finally, Suvretta Capital Management LLC raised its position in Fulcrum Therapeutics by 5.9% in the 3rd quarter. Suvretta Capital Management LLC now owns 5,381,000 shares of the company's stock valued at $49,505,000 after purchasing an additional 298,100 shares during the last quarter. Institutional investors own 89.83% of the company's stock.

Fulcrum Therapeutics Trading Down 3.6%

Shares of NASDAQ:FULC opened at $7.44 on Wednesday. Fulcrum Therapeutics has a 1-year low of $3.54 and a 1-year high of $15.74. The firm has a market capitalization of $495.50 million, a PE ratio of -6.47 and a beta of 3.27. The business's 50 day moving average is $8.00 and its 200-day moving average is $9.54.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last announced its quarterly earnings data on Monday, April 27th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.06. On average, sell-side analysts predict that Fulcrum Therapeutics will post -1.28 EPS for the current year.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company's core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum's most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.